S Saab

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis
    S Saab
    Departments of Medicine and Physiology, Division of Digestive Diseases, University of California Los Angeles, CA, USA
    Am J Kidney Dis 37:308-15. 2001
  2. ncbi Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model
    Sammy Saab
    Department of Medicine, Dumont UCLA Liver Transplant Center, University of California Los Angeles, USA
    Liver Transpl 9:672-81. 2003
  3. ncbi Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options
    Sammy Saab
    MPH Division of Digestive Diseases 44 138 CHS MC 168417, UCLA Medical Center, 10833 Le Conte Avenue Los Angeles, CA 90095, USA
    J Clin Gastroenterol 37:155-63. 2003
  4. ncbi The cost effectiveness of hepatitis immunization for US college students
    R Jake Jacobs
    Capitol Outcomes Research, Alexandria, Virginia 22310, USA
    J Am Coll Health 51:227-36. 2003
  5. ncbi Primary prevention of cirrhosis. Public health strategies that can make a difference
    Hetal A Karsan
    Division of Digestive Diseases, University of California, Los Angeles, David Geffen School of Medicine, USA
    Postgrad Med 115:25-30. 2004
  6. ncbi Trends in viral hepatitis cost-effectiveness studies
    Sammy Saab
    Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, 200 Medical Plaza, Ste 214, Los Angeles, CA 90095 7302, USA
    Am J Manag Care 18:790-8. 2012
  7. ncbi Management of patients with cirrhosis in Southern California: results of a practitioner survey
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA
    J Clin Gastroenterol 40:156-61. 2006
  8. ncbi Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis
    Sammy Saab
    Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Am J Gastroenterol 104:993-1001; quiz 1002. 2009
  9. ncbi Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation
    Sammy Saab
    Department of Medicine, Division of Digestive Diseases, Dumont UCLA Liver Transplant Center, University of California Los Angeles, 90095, USA
    Liver Transpl 9:1053-61. 2003
  10. ncbi Decision analysis model for hepatitis B prophylaxis one year after liver transplantation
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Liver Transpl 15:413-20. 2009

Detail Information

Publications96

  1. ncbi Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis
    S Saab
    Departments of Medicine and Physiology, Division of Digestive Diseases, University of California Los Angeles, CA, USA
    Am J Kidney Dis 37:308-15. 2001
    ..A newly elevated aminotransferase level was neither sensitive nor positively predictive of chronic infection. Therefore, an elevated ALT level is an ineffective method for screening for HCV infection in HD patients...
  2. ncbi Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model
    Sammy Saab
    Department of Medicine, Dumont UCLA Liver Transplant Center, University of California Los Angeles, USA
    Liver Transpl 9:672-81. 2003
    ..U/S screening strategy is the preferred screening strategy based on the lowest ICER. Ultimately, costs of the screening modalities determine the most cost-effective strategy...
  3. ncbi Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options
    Sammy Saab
    MPH Division of Digestive Diseases 44 138 CHS MC 168417, UCLA Medical Center, 10833 Le Conte Avenue Los Angeles, CA 90095, USA
    J Clin Gastroenterol 37:155-63. 2003
    ..Higher efficacy has been associated with combination therapy for recurrent disease. Adverse effects limit its widespread use...
  4. ncbi The cost effectiveness of hepatitis immunization for US college students
    R Jake Jacobs
    Capitol Outcomes Research, Alexandria, Virginia 22310, USA
    J Am Coll Health 51:227-36. 2003
    ..Until childhood and adolescent vaccination can produce immune cohorts of young adults, college-based hepatitis immunization can reduce disease transmission in a cost-effective manner...
  5. ncbi Primary prevention of cirrhosis. Public health strategies that can make a difference
    Hetal A Karsan
    Division of Digestive Diseases, University of California, Los Angeles, David Geffen School of Medicine, USA
    Postgrad Med 115:25-30. 2004
    ..In this article, Drs Karsan, Rojter, and Saab examine lifestyle behaviors that can lead to cirrhosis and enumerate public health strategies aimed at primary prevention...
  6. ncbi Trends in viral hepatitis cost-effectiveness studies
    Sammy Saab
    Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, 200 Medical Plaza, Ste 214, Los Angeles, CA 90095 7302, USA
    Am J Manag Care 18:790-8. 2012
    ..Objectives: To determine whether studies that reported favorable cost-effectiveness results in the antiviral treatment of hepatitis B and hepatitis C were more likely to be published...
  7. ncbi Management of patients with cirrhosis in Southern California: results of a practitioner survey
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA
    J Clin Gastroenterol 40:156-61. 2006
    ..A paucity of data exists on how patients with cirrhosis are managed. Our aims were to determine how cirrhosis is managed and whether current management practices follow established recommendations...
  8. ncbi Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis
    Sammy Saab
    Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Am J Gastroenterol 104:993-1001; quiz 1002. 2009
    ..Through subgroup analysis, we also evaluated the effect of prophylactic oral antibiotic therapy on the prevention of SBP and the incidence of all infections (including SBP) when compared with non-treated or placebo controls...
  9. ncbi Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation
    Sammy Saab
    Department of Medicine, Division of Digestive Diseases, Dumont UCLA Liver Transplant Center, University of California Los Angeles, 90095, USA
    Liver Transpl 9:1053-61. 2003
    ..Furthermore, the use of combined HBcAb+/HCV+ grafts did not impact patient or graft survival. This provides a potential new pool of donor livers that can be used for transplantation in select patients...
  10. ncbi Decision analysis model for hepatitis B prophylaxis one year after liver transplantation
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Liver Transpl 15:413-20. 2009
    ....
  11. ncbi Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis
    Sammy Saab
    Division of Digestive Diseases, Dumont UCLA Liver Transplant Center, University of California, Los Angeles, CA 90095, USA
    Am J Transplant 3:1167-72. 2003
    ..Our results suggest that HCV-positive grafts can be used in a HCV liver transplant recipient...
  12. ncbi Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation
    Sammy Saab
    Department of Medicine, University of California, Los Angeles, CA, USA
    Liver Transpl 15:1525-34. 2009
    ..Hepatitis B immunoglobulin and antiviral therapy was only partially effective in preventing HBV reinfection in patients with HCC recurrence...
  13. ncbi MELD score predicts 1-year patient survival post-orthotopic liver transplantation
    Sammy Saab
    Division of Digestive Diseases, University of California Los Angeles, Los Angeles, CA, USA
    Liver Transpl 9:473-6. 2003
    ..99; 95% CI 1.07, 3.7). The MELD stratum is better associated with 1-year patient survival in liver transplant recipients than UNOS statuses. Patient survival was worse with higher MELD scores...
  14. ncbi Pretransplant variables associated with quality of life in liver transplant recipients
    Sammy Saab
    Department of Medicine, University of California, Los Angeles, CA 90095, USA
    Liver Int 28:1087-94. 2008
    ..Our goal is to identify pretransplant variables associated with post-transplant quality of life in liver transplant recipients...
  15. ncbi Employment and quality of life in liver transplant recipients
    Sammy Saab
    Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Liver Transpl 13:1330-8. 2007
    ....
  16. ncbi The MELD score in advanced liver disease: association with clinical portal hypertension and mortality
    Sammy Saab
    Department of Medicine, University of California at Los Angeles 90095, and Department of Medicine at Olive View Medical Center, Pasadena, USA
    Exp Clin Transplant 4:395-9. 2006
    ..However, clinical factors that affect the MELD score are unknown. We sought to identify predictors of mortality for potential transplant patients and examine factors that might predict changes in MELD score...
  17. ncbi Lymphedema tarda after liver transplantation: a case report and review of the literature
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California 90095 7302, USA
    Exp Clin Transplant 4:567-70. 2006
    ..In the patient we describe, lymphedema tarda, which was diagnosed 6 months after liver transplantation, was likely caused by chylous ascites and a developmental abnormality of the lymphatic system...
  18. ncbi MELD fails to measure quality of life in liver transplant candidates
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    Liver Transpl 11:218-23. 2005
    ..The presence of ascites and/or encephalopathy was significantly associated with poor quality of life. CTP correlates better to QOL, probably because it contains ascites and encephalopathy...
  19. ncbi Same day outpatient transjugular liver biopsies in haemophilia
    S Saab
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Haemophilia 10:727-31. 2004
    ..6 and mean stage was 2.3 +/- 1.2. Our experience demonstrates that outpatient transjugular liver biopsy can be safely performed in patients with haemophilia in the outpatient setting, avoiding the cost and need for hospital admission...
  20. ncbi Outcomes of acute rejection after interferon therapy in liver transplant recipients
    Sammy Saab
    Department of Medicine, Dumont UCLA Liver Transplant Center, Los Angeles, CA, USA
    Liver Transpl 10:859-67. 2004
    ..Interferon-based therapy may lead to acute rejection and subsequent graft loss and should therefore be used with caution. Treated recipients may also develop progressive cirrhosis despite achieving a sustained virological response...
  21. ncbi Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C
    Sammy Saab
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Liver Transpl 13:1032-8. 2007
    ..01) and age (P = 0.02) were found to be independent predictors of anemia. Anemia is common in liver transplant recipients treated for recurrent HCV. Special vigilance is required for older patients and patients with a low BMI...
  22. ncbi Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis
    Sammy Saab
    Division of Digestive Diseases, Department of Medicine, UCLA Medical Center, University of California Los Angeles, 200 Medical Plaza, Los Angeles, CA 90095, USA
    Liver Int 25:940-5. 2005
    ..The aim of this study was to identify predictors of survival in liver transplant recipients who develop cirrhosis from recurrent HCV...
  23. ncbi Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model
    Sammy Saab
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Hepatology 46:1049-56. 2007
    ..CONCLUSION: Our results provide pharmacoeconomic support for the use of lamivudine prophylaxis in patients undergoing chemotherapy for lymphoma treatment...
  24. ncbi Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Liver Transpl 16:300-7. 2010
    ..Nucleoside analogue monotherapy should therefore be considered when one is treating HBV(-) patients who have received liver allografts from HBcAb(+) donors...
  25. ncbi Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model
    Sammy Saab
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Liver Transpl 16:748-59. 2010
    ..This study provides pharmacoeconomic evidence in support of treating HCV in patients with compensated cirrhosis before progression to more advanced liver disease...
  26. ncbi Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus
    S Saab
    Division of Digestive Diseases, and University of California San Francisco, San Francisco, California 90095, USA
    Gastroenterology 119:1382-4. 2000
    ..Our experience suggests that the emergence of a YMDD HBV mutant is not a contraindication to OLT. The combination of lamivudine and high-dose HBIG can protect against reinfection of the hepatic allograft with the YMDD HBV escape mutant...
  27. ncbi Seroepidemiology of hepatitis A in patients with chronic liver disease
    S Saab
    Division of Digestive Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Viral Hepat 12:101-5. 2005
    ..We demonstrated that age-stratified seroprevalence of HAV in patients with CLD of various aetiologies is significantly higher than that of the general population, and identified several independent predictors of HAV prior exposure...
  28. ncbi Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
    Sammy Saab
    Department of Medicine, University of California Los Angeles, USA
    Liver Transpl 8:449-57. 2002
    ..Our model was sensitive to antiviral drug costs, cirrhosis rate, and sustained viral response. Patients with a progressive course of recurrent HCV are likely to have the greatest gain from antiviral therapy...
  29. ncbi Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients
    Sammy Saab
    Department of Medicine, Los Angeles School of Medicine, University of California, Los Angeles, CA 90095, USA
    Vaccine 20:3230-5. 2002
    ..The results of our model did not support our hypothesis, and indicate that regularly screening patients for HBV immunity before revaccination is less costly and more effective than the empiric vaccination of hemodialysis patients...
  30. ncbi Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors
    Sammy Saab
    Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA
    Liver Transpl 17:580-90. 2011
    ....
  31. ncbi Development of a disease-specific questionnaire to measure health-related quality of life in liver transplant recipients
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Liver Transpl 17:567-79. 2011
    ..The pLTQ instrument is applicable to a variety of liver transplant recipients. The questionnaire was tested with a cross-sectional and longitudinal approach...
  32. ncbi Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy
    S Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, CA, USA
    Am J Transplant 11:511-7. 2011
    ..The clinical implications of HBsAg detection without clinical, biochemical or molecular manifestations of recurrent hepatitis B require further study...
  33. ncbi Practical management of liver transplant recipients for hepatitis C
    S Saab
    Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, USA
    Minerva Chir 58:479-89. 2003
    ..Advances in antiviral therapy are now associated with a sustained virological response of 20% with combination antiviral with interferon and ribavirin. Higher response rates are expected with utilizing pegylated interferon...
  34. ncbi Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C
    Sammy Saab
    Department of Medicine, Dumont UCLA Liver Transplant Center, University of California Los Angeles, USA
    Am J Transplant 3:328-33. 2003
    ..Our results suggest that HCV disease can progress despite a significant decrease in ALT values. ALT values are inadequate markers of the ribavirin monotherapy and can lead to erroneous conclusions of efficacy...
  35. ncbi Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Sammy Saab
    Departments of Medicine, The University of California at Los Angeles, Los Angeles, CA, USA
    Exp Clin Transplant 8:307-13. 2010
    ..Liver transplant can be a definitive treatment for hepatocellular carcinoma. However, recurrence limits long-term survival. Sorafenib is the first agent to improve survival for patients with advanced hepatocellular carcinoma...
  36. ncbi A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients
    R M Ghobrial
    Dumont-UCLA Transplant Center, Department of Surgery, UCLA School of Medicine, Los Angeles, California 90095, USA
    Ann Surg 234:384-93; discussion 393-4. 2001
    ..Graft survival is affected by donor gender, warm ischemia time, and pretransplant patient condition. The authors' current survival prognostic models require further multicenter validation...
  37. ncbi A cost-effectiveness analysis of biliary anastomosis with or without T-tube after orthotopic liver transplantation
    M Shimoda
    The Dumont-UCLA Liver and Pancreas Transplant Center, University of California Los Angeles, 90095, USA
    Am J Transplant 1:157-61. 2001
    ..It is not only associated with fewer biliary complications, but also less costly than using choledochocholedochostomy over a T-tube. Randomized prospective studies are needed to confirm our results...
  38. ncbi Endoscopic management of biliary leaks after T-tube removal in liver transplant recipients: nasobiliary drainage versus biliary stenting
    S Saab
    Division of Digestive Diseases and Dumont University of California at Los Angeles Transplant Program, Los Angeles, CA 90095, USA
    Liver Transpl 6:627-32. 2000
    ..However, our results suggest NBD is the preferred method because recurrent leaks were more common in patients treated initially with BS. With prompt use of ERCP, surgery is rarely needed for this complication of OLT...
  39. ncbi The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis
    A I Kim
    Division of Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    HIV Med 8:312-21. 2007
    ....
  40. ncbi Hepatitis C screening strategies in hemodialysis patients
    S Saab
    Departments of Medicine and Physiology, Division of Digestive Diseases, University of California at Los Angeles, USA
    Am J Kidney Dis 38:91-7. 2001
    ..Serological-based screening should be considered for HCV screening in hemodialysis populations...
  41. ncbi Evidence-based incorporation of serum sodium concentration into MELD
    Scott W Biggins
    University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1652-60. 2006
    ..CONCLUSIONS: We demonstrate an evidence-based method to incorporate Na into MELD, which provides more accurate survival prediction than MELD alone...
  42. ncbi New era of liver transplantation for hepatitis B: a 17-year single-center experience
    Dean M Anselmo
    Department of Surgery, Dumont-UCLA Liver Transplant Center, UCLA School of Medicine, Los Angeles, California 90095-7054, USA
    Ann Surg 235:611-9; discussion 619-20. 2002
    ..Viral prophylactic therapy has effectively reduced HBV recurrence and prolonged survival outcomes. The combination of HBIg and lamivudine is the prophylactic regimen of choice...
  43. ncbi Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis
    Myron John Tong
    The Pfleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA
    Dig Dis Sci 54:1337-46. 2009
    ..Hepatitis B viral markers and liver tests were used as predictors for development of hepatocellular carcinoma and progression to end-stage liver disease in 128 cirrhosis patients with hepatitis B...
  44. ncbi Major challenges limiting liver transplantation in the United States
    J A Wertheim
    Dumont UCLA Transplant Center, Division of Liver and Pancreas Transplantation, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Am J Transplant 11:1773-84. 2011
    ....
  45. ncbi Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib
    M Yeganeh
    Department of Medicine, University of California, Los Angeles, CA, USA
    Am J Transplant 9:2851-4. 2009
    ..We report complete remission of HCC in a 54-year-old man who developed biopsy-proven lung metastasis after liver transplantation treated with sorafenib...
  46. ncbi Treating hepatitis C in the prison population is cost-saving
    Jennifer A Tan
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Hepatology 48:1387-95. 2008
    ..If the decision to treat hepatitis C is based on pharmaco-economic measures, this significant proportion of infected individuals should not be denied access to therapy...
  47. ncbi Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors
    John P Duffy
    Department of Surgery, Dumont UCLA Transplant Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Ann Surg 252:652-61. 2010
    ..To evaluate patient survival and allograft function and health-related quality of life (HRQOL) 20 years after orthotopic liver transplantation (LT)...
  48. ncbi Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C
    Mitsugi Shimoda
    Dumont-UCLA Liver Transplant Center, Department of Surgery, UCLA School of Medicine, 90095, USA
    Liver Transpl 10:1478-86. 2004
    ..Early pTNM stage, adjuvant chemotherapy, and preoperative chemoembolization were associated with positive outcomes for patients who underwent OLT for concomitant HCV and HCC...
  49. ncbi Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  50. ncbi Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost
    Patrick G Northup
    Department of Medicine, University of Virginia, Charlottesville, VA, USA
    Liver Transpl 15:148-62. 2009
    ..The addition of LDLT to a standard waiting list DDLT program is effective at improving recipient survival and preventing waiting list deaths but at a greater cost...
  51. ncbi Liver transplantation. Selection, listing criteria, and preoperative management
    S Saab
    Division of Digestive Diseases, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Clin Liver Dis 4:513-32. 2000
    ....
  52. ncbi Pretransplant model to predict posttransplant survival in liver transplant patients
    Rafik M Ghobrial
    Dumont-UCLA Transplant Center, Department of Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Ann Surg 236:315-22; discussion 322-3. 2002
    ....
  53. ncbi Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model
    Sammy Saab
    Division of Digestive Diseases, Department of Medicine, Dumont-UCLA Liver Transplant Center, Los Angeles, CA 90095, USA
    Am J Gastroenterol 98:763-70. 2003
    ..Universal prophylaxis with beta-blocker is preferred because it is consistently associated with the lowest costs and highest QALYs...
  54. ncbi Treatment of hepatitis C
    Andrew I Kim
    Department of Medicine, West Los Angeles VA Medical Center, Los Angeles, California, USA
    Am J Med 118:808-15. 2005
    ..The substantial adverse effects associated with both interferon alfa and ribavirin often make it difficult for patients to continue with their therapies...
  55. ncbi Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization
    David Ly
    Department of Medicine, University of California, Los Angeles 90095, USA
    Am J Gastroenterol 97:138-41. 2002
    ..Hemodialysis patients should not be screened for HBV within a week of immunization, and caution should be exercised when interpreting HBsAg seropositivity within 4 wk of HBV immunization...
  56. ncbi Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation
    S Saab
    Division of Digestive Diseases, University of California Los Angeles, USA
    Am J Transplant 6:1890-5. 2006
    ..Follow-up studies are needed to assess the impact of diabetes, and its intervention on post-transplant morbidity and mortality...
  57. ncbi Feasibility of completing an accelerated vaccine series for homeless adults
    A M Nyamathi
    School of Nursing, University of California, Los Angeles, CA, USA
    J Viral Hepat 16:666-73. 2009
    ..The use of nurse case-management and tracking, coupled with an accelerated HAV/HBV vaccination schedule, may optimize vaccination compliance in homeless adults...
  58. ncbi Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults
    Adeline Nyamathi
    School of Nursing, University of California Los Angeles, Los Angeles, CA 90095 1702, USA
    Nurs Res 58:13-22. 2009
    ..Ability to complete an HBV vaccination series is complicated by the need to prioritize competing needs, such as addiction issues, safe places to sleep, and food, over health concerns...
  59. ncbi A model to predict the development of mental status changes of unclear cause after liver transplantation
    Fasiha Kanwal
    Division of Digestive Diseases, David Geffen School of Medicine at University of California at Los Angeles, CA, USA
    Liver Transpl 9:1312-9. 2003
    ..A simple model can be used to calculate the risk for developing altered mental status post-LT...
  60. ncbi Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation
    Steven Huy Han
    Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA
    Liver Transpl 9:182-7. 2003
    ....
  61. ncbi Endoscopic treatment with multiple stents for post-liver-transplantation nonanastomotic biliary strictures
    James H Tabibian
    Dumont University of California Los Angeles Liver Transplant Center and UCLA Division of Digestive and Liver Diseases, Los Angeles, California, USA
    Gastrointest Endosc 69:1236-43. 2009
    ..Although data strongly support ERCP for treating anastomotic strictures, the little information available for the role of ERCP in the treatment of nonanastomotic strictures (NAS) has been unpromising...
  62. ncbi The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients
    Hillary Bownik
    Department of Medicine, University of California, Los Angeles, CA 90095, USA
    Liver Int 30:19-30. 2010
    ..Understanding modifiable factors on HRQOL after HCV recurrence in OLT patients can greatly aid in tailoring multidimensional interventions to improve patient HRQOL...
  63. ncbi Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period
    Douglas G Farmer
    Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Ann Surg 237:666-75; discussion 675-6. 2003
    ..To analyze outcomes after liver transplantation (LT) in patients with fulminant hepatic failure (FHF) with emphasis on pretransplant variables that can potentially help predict posttransplant outcome...
  64. ncbi Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video)
    James H Tabibian
    Dumont UCLA Liver Transplant Center, Los Angeles, California, USA
    Gastrointest Endosc 71:505-12. 2010
    ..The optimal endoscopic protocol for treating postorthotopic liver transplantation (OLT) anastomotic biliary strictures (ABSs) has not been established...
  65. ncbi Presence and predictors of hepatitis C virus RNA in the semen of homeless men
    Adeline Nyamathi
    School of Nursing, University of California, Los Angeles 90095 1702, USA
    Biol Res Nurs 4:22-30. 2002
    ..Findings suggest that sexual transmission of HCV is plausible and shed light on the need to conduct more in-depth investigations...
  66. ncbi Donor and recipient outcomes in right lobe adult living donor liver transplantation
    Rafik M Ghobrial
    Department of Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Liver Transpl 8:901-9. 2002
    ..Continuous standardized reporting of ALDLT outcomes is required to allow successful and safe implementation of the procedure...
  67. ncbi Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores
    Francis Y Yao
    Department of Medicine University of California, San Francisco, San Francisco, CA, USA
    Hepatology 39:230-8. 2004
    ..In conclusion, our results suggest that severity of graft failure based on CTP and MELD scores may be associated with worse outcome after re-OLT and provide a cautionary note for the "sickest first" policy of organ allocation...
  68. ncbi Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma
    Francisco A Durazo
    The Pfleger Liver Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Gastroenterol Hepatol 23:1541-8. 2008
    ....
  69. ncbi Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation
    David S K Lu
    Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Hepatology 41:1130-7. 2005
    ..This can be attributed to the efficacy of RFA in producing local cure or curbing tumor progression during the waiting period...
  70. ncbi Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience
    Ronald W Busuttil
    Dumont UCLA Liver Transplant Center, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Ann Surg 241:905-16; discussion 916-8. 2005
    ..This work analyzes the experience of nearly 2 decades by the same team in a single center. Outcomes of OLT and factors affecting survival were analyzed...
  71. ncbi Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial
    Temitope Foster
    Department of Medicine, University of California, Los Angeles, California 90095, USA
    Am J Gastroenterol 106:71-7. 2011
    ..Currently, there is no proven therapy for NAFLD. In this study, we aim to determine whether statin therapy may be an effective treatment for NAFLD and identify independent predictors of NAFLD...
  72. ncbi A proposed, evidence-based approach to the treatment of chronic Hepatitis B
    Steven Huy B Han
    Division of Digestive Diseases, Pfleger Liver Institute, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA
    J Clin Gastroenterol 45:259-66. 2011
    ..We present a new treatment strategy for determining the need for antiviral therapy in patients with chronic hepatitis B...
  73. ncbi Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma
    Lenna A Martyak
    Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:900-5. 2009
    ..Other factors such as gene translocation, somatic hypermutation and direct infection may also play a role in the malignant transformation of B-cells...
  74. ncbi Liver transplantation in the era of model for end-stage liver disease
    Victor S Wang
    VA Greater Los Angeles Health Care System, University of California, Los Angeles, CA, USA
    Liver Int 24:1-8. 2004
    ..Currently, liver allocation in the United States is based on the model for end-stage liver disease (MELD). Studies have shown MELD to be objective and accurate in predicting short-term survival in patients with cirrhosis...
  75. ncbi Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management
    Shireena Desai
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Liver Int 30:948-57. 2010
    ..However, the prevalence of post-transplant cardiovascular complications has been rising with increased life expectancy after liver transplantation...
  76. ncbi Viral hepatitis in incarcerated adults: a medical and public health concern
    Douglas R Hunt
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California, USA
    Am J Gastroenterol 104:1024-31. 2009
    ..In this article, the published medical literature regarding this important topic is reviewed...
  77. ncbi Preoperative imaging in adult-to-adult living related liver transplant donors: what surgeons want to know
    Piyaporn Limanond
    Department of Radiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 1721, USA
    J Comput Assist Tomogr 28:149-57. 2004
    ..The roles of high-field magnetic resonance (MR) imaging, MR angiography, MR cholangiopancreatography, multidetector-row computed tomography (CT) angiography, and CT cholangiography in the workup are discussed...
  78. ncbi Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis
    Lenna A Martyak
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Liver Int 28:28-38. 2008
    ..Lamivudine has been suggested to be useful as a prophylaxis for HBV reactivation; however, its impact on overall survival and HBV reactivation-related liver disease survival is unclear...
  79. ncbi Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings
    Piyaporn Limanond
    Department of Radiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1721, USA
    Radiology 230:276-80. 2004
    ..Core liver biopsy is still necessary in the majority of donors with normal LAI to identify those with both fatty liver and coexistent hemosiderin deposition or radiologically occult diffuse liver diseases...
  80. ncbi Pregnancy and cirrhosis
    Jennifer Tan
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Liver Transpl 14:1081-91. 2008
    ..Pregnancy outcome may be influenced by the underlying etiology of liver disease, as in viral and autoimmune hepatitis. Medications also impact the course of pregnancy, and must be tailored appropriately during this time...
  81. ncbi Effect of nonviral factors on hepatitis C recurrence after liver transplantation
    Andrew M Cameron
    Department of Surgery, Dumont-UCLA Liver Transplant Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Ann Surg 244:563-71. 2006
    ..A change in the current national liver allocation system would be needed to realize the full value of this benefit...
  82. ncbi Health-related quality of life after liver transplantation for adult recipients
    Hillary Bownik
    Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Liver Transpl 15:S42-9. 2009
    ..9. The development of a health-related quality of life assessment tool specific to transplantation could help us to more accurately assess factors (such as immunosuppression) that alter posttransplantation health-related quality of life...
  83. ncbi Tests for acute and chronic viral hepatitis. Finding your way through the alphabet soup of infection and superinfection
    S Saab
    Division of Digestive Diseases, UCLA School of Medicine, USA
    Postgrad Med 107:123-6, 129-30. 2000
    ..Knowledge of the strengths and limitations of these tests allows rational use and interpretation of results. The findings have implications for public health surveillance, estimating prognosis, and identifying candidates for treatment...
  84. ncbi Fulminant liver failure due to usnic acid for weight loss
    Francisco A Durazo
    Division of Digestive Diseases, Department of Medicin, Dumont-UCLA Liver Transplant Center, University of California, Los Angeles, California 90095-9302, USA
    Am J Gastroenterol 99:950-2. 2004
    ..A discussion about hepatotoxicity of the different compounds of dietary supplements is presented. This is a reminder for the clinicians about the potential side effects of CAM...
  85. ncbi Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO 80262, and Department of Transplant Services, Piedmont Hospital, Atlanta, GA, USA
    Transplantation 83:1506-8. 2007
    ....
  86. ncbi Immunization needs of chronic liver disease patients seen in primary care versus specialist settings
    R Jake Jacobs
    Capitol Outcomes Research, Inc, Alexandria, Virginia 22310, USA
    Dig Dis Sci 50:1525-31. 2005
    ..The higher coverage rates evident in centers vaccinating on-site suggests a breakdown may occur when patients are referred to alternative vaccination venues...
  87. ncbi Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients
    Yong Yuan
    Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    J Manag Care Pharm 14:21-33. 2008
    ..Entecavir has demonstrated greater suppression of viral replication compared with lamivudine, but also has a relatively higher drug acquisition cost in the United States...
  88. ncbi An economic assessment of pre-vaccination screening for hepatitis A and B
    R Jake Jacobs
    Capitol Outcomes Research, Inc, Alexandria, VA 22310, USA
    Public Health Rep 118:550-8. 2003
    ....
  89. ncbi Complications of cirrhosis
    Mamie H Dong
    Dis Mon 54:445-56. 2008
  90. ncbi Postresection hepatic failure: successful treatment with liver transplantation
    Yuichiro Otsuka
    Department of Surgery, Toho University School of Medicine, Tokyo, Japan
    Liver Transpl 13:672-9. 2007
    ..In conclusion, patients with low platelets, biopsy-proven cirrhosis, or those undergoing extended resection are at increased risk for PLF. OLT for PLF has significant morbidity but allows salvage of an otherwise fatal condition...
  91. ncbi Regional variation in the cost effectiveness of childhood hepatitis A immunization
    R Jake Jacobs
    Capitol Outcomes Research, Inc, Alexandria, VA 22310, USA
    Pediatr Infect Dis J 22:904-14. 2003
    ..Routine childhood hepatitis A immunization is recommended in regions with incidence rates twice the national average, but it may be cost-effective in a wider geographic area...
  92. ncbi Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient
    Sammy Saab
    J Hepatol 42:148-9. 2005
  93. ncbi A parathyroid hormone-related protein-secreting metastatic epithelioid leiomyosarcoma. A case report and review of the literature
    Shou Jiang Tang
    Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, USA
    Arch Pathol Lab Med 127:e181-5. 2003
    ..Extensive biochemical analysis and detailed immunohistochemical and ultrastructural characterization demonstrate several features of this tumor...
  94. ncbi Ammonia levels and the severity of hepatic encephalopathy
    Victor Wang
    Am J Med 114:237-8. 2003
  95. ncbi Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1
    Sammy Saab
    Department of Medicine, UCLA School of Medicine, Los Angeles, Calif 90095, USA
    J Biomed Sci 9:607-12. 2002
    ..These results suggest that endothelin-1-stimulated contractile force generation by stellate cells is mediated by myosin...
  96. ncbi Outcomes of donor evaluation in adult-to-adult living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO, USA
    Hepatology 46:1476-84. 2007
    ..CONCLUSION: Both donor and recipient features appear to affect acceptance for LDLT. These findings may aid the donor evaluation process and allow an objective assessment of the likelihood of donor candidate acceptance...